Skip to content

Analysis of the Efficacy of Radiofrequency Ablation Guided by Ultrasound for Uterine Fibroids and Related Influencing Factors

Analysis of the Efficacy of Radiofrequency Ablation Guided by Ultrasound for Uterine Fibroids and Related Influencing Factors

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600123736
Enrollment
Unknown
Registered
2026-04-29
Start date
2026-04-30
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

uterine fibroids

Interventions

Group of Patients with Uterine Fibroids Treated by Ultrasound-Guided Radiofrequency Ablation:no

Sponsors

The First Affiliated Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Uterine fibroids diagnosed clearly by magnetic resonance imaging (MRI) and ultrasound examination; 2. It is accompanied by one of the symptoms such as menorrhagia, secondary anemia, abdominal pain, and compression; 3. Patients have no perimenopausal signs; 4. There is a safe transabdominal puncture path. 5. Uterine fibroid symptoms and health-related quality of life questionnaire (UFS-QOL) and menstrual score (PBAC) ratings were performed; 6. Patients are unable to operate or refuse surgery themselves.

Exclusion criteria

Exclusion criteria: 1. Suffering from malignant uterine lesions (such as uterine sarcoma, uterine fibroids with cervical cancer or endometrial cancer or ovarian cancer and other gynecological malignancies). 2. Severe chronic diseases; 3. Menstruation, pregnancy or lactation; 4. There is no safe percutaneous puncture path (the lesion is adherent to important organs such as intestinal tract, bladder, and large blood vessels and cannot be separated); 5. Uncontrolled acute pelvic inflammation; 6. Dysfunction of important1. organs such as liver and kidney; 7. Metal devices implanted in the body, including IUDs; 8. Severe coagulation dysfunction, platelet 25 s, prothrombin activity < 40%.

Design outcomes

Primary

MeasureTime frame
The rate of volume reduction has significantly increased.;Improvement of clinical symptoms;

Secondary

MeasureTime frame
Incidence of adverse events;

Countries

China

Contacts

Public ContactDu Linyao

The First Affiliated Hospital of Dalian Medical University

dulinyao@firsthosp-dmu.com+86 411 83635963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026